Why the study?
To evaluate the prevalence of the CYP2C19*2 genetic polymorphism in ischaemic heart disease patients and assess its relation to clopidogrel resistance across genotype groups.
Does CYP2C19*2 genetic polymorphism affect clopidogrel resistance in Pakistani patients with ischemic heart disease?
Population
390 ischaemic heart disease patients on clopidogrel therapy
Comparison
Homozygous wild type (*1/*1) vs heterozygous (*1/*2) vs homozygous polymorphic (*2/*2) carriers
Design
Cross-sectional study
Authors
Loading...
The CYP2C19*2 polymorphism is highly prevalent in Pakistani ischemic heart disease patients and is significantly associated with increased clopidogrel resistance.
Does CYP2C19*2 genetic polymorphism affect clopidogrel resistance in Pakistani patients with ischemic heart disease?
The CYP2C19*2 polymorphism is highly prevalent in Pakistani ischemic heart disease patients and is significantly associated with increased clopidogrel resistance.
Nawaz et al. (2023) studied this question.